Search results for: Mary-Carmen Amigo

Items from 1 to 16 out of 16 results

article

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, more

Arthritis & Rheumatology > 75 > 10 > 1687 - 1702

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by...

article

Developing and improving the ethical framework for the ISTH

Ze Zheng, Nicoletta Riva, Ecaterina Scarlatescu, Philippe Moerloose, more

Journal of Thrombosis and Haemostasis > 20 > 8 > 1753 - 1754

article

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

Medha Barbhaiya, Stephane Zuily, Yasaman Ahmadzadeh, Mary‐Carmen Amigo, more

Arthritis Care & Research > 73 > 10 > 1490 - 1501

Objective An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence‐ and consensus‐based...

article

Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part I

Miguel Ángel Saavedra Salinas, Antonio Barrera Cruz, Antonio Rafael Cabral Castañeda, Luis Javier Jara Quezada, more

Reumatologia clinica (English Edition) > 2015 > 11 > 5 > 295-304

Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and foetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients.To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus (SLE),...

article

Clinical Practice Guidelines for the Management of Pregnancy in Women With Autoimmune Rheumatic Diseases of the Mexican College of Rheumatology. Part II

Miguel Ángel Saavedra Salinas, Antonio Barrera Cruz, Antonio Rafael Cabral Castañeda, Luis Javier Jara Quezada, more

Reumatologia clinica (English Edition) > 2015 > 11 > 5 > 305-315

article

The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features

Mirhelen M. Abreu, Adriana Danowski, Denis G. Wahl, Mary-Carmen Amigo, more

Autoimmunity Reviews > 2015 > 14 > 5 > 401-414

The purpose of this task force was to critically analyze nine non-criteria manifestations of APS to support their inclusion as APS classification criteria. The Task Force Members selected the non-criteria clinical manifestations according to their clinical relevance, that is, the patient-important outcome from clinician perspective. They included superficial vein thrombosis, thrombocytopenia, renal...

article

Cardiac valve replacement in patients with antiphospholipid syndrome

José‐Gabriel Erdozain, Guillermo Ruiz‐Irastorza, Maria‐Isabel Segura, Mary‐Carmen Amigo, more

Arthritis Care & Research > 64 > 8 > 1256 - 1260

ObjectiveTo analyze the results of cardiac valve replacement in a multicenter cohort of patients with antiphospholipid syndrome (APS) and to identify prognostic factors of poor outcome. MethodsWe performed a retrospective analysis of clinical manifestations (cardiac involvement and APS characteristics), operative and early postoperative courses, and long‐term followup. All of the patients fulfilled...

article

Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography

Erick Alexanderson, Patricio Cruz, Angélica Vargas, Aloha Meave, more

Journal of Nuclear Cardiology > 2007 > 14 > 4 > 566-572

There is limited knowledge about endothelial dysfunction in patients with primary antiphospholipid syndrome (PAPS). The purpose of this study was to evaluate endothelial function in patients with PAPS assessed by positron emission tomography.A 3-phase protocol—rest, cold pressor test (CPT), and adenosine positron emission tomography with nitrogen 13 ammonia—was used in 18 patients with PAPS and 18...

article

The Heart and APS

Mary-Carmen Amigo

Clinical Reviews in Allergy & Immunology > 2007 > 32 > 2 > 178-183

The heart is a target organ in antiphospholipid syndrome (APS). Endocardial disease, intracardiac thrombosis, myocardial involvement including coronary heart disease and microvascular thrombosis, as well as pulmonary hypertension have all been described in APS patients. Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical,...

article

Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography

Erick Alexanderson, Patricio Cruz, Angélica Vargas, Aloha Meave, more

Journal of Nuclear Cardiology > 2007 > 14 > 4 > 566-572

Background There is limited knowledge about endothelial dysfunction in patients with primary antiphospholipid syndrome (PAPS). The purpose of this study was to evaluate endothelial function in patients with PAPS assessed by positron emission tomography. Methods and Results A 3-phase protocol—rest, cold pressor test (CPT), and adenosine positron emission tomography with nitrogen 13 ammonia—was used...

article

Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases

Luis J. Jara, Gabriela Medina, Olga Vera-Lastra, Mary-Carmen Amigo

Autoimmunity Reviews > 2006 > 5 > 3 > 195-201

Atherosclerosis (AT) is a chronic autoimmune inflammatory disease, characterized by lipoproteins metabolism alteration leading to formation of pro-inflammatory and pro-oxidative lipids and immune response. Identification of macrophages, T cells, pro-inflammatory cytokines, adhesion cell molecules in atherosclerotic lesions support the hypothesis that innate and adaptive immune response participate...

article

Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: Relationship to pathogenesis

Mary-Carmen Amigo, Romeo García-Torres

Current Rheumatology Reports > 2000 > 2 > 3 > 262-270

A growing body of evidence suggests that aPL are not only serological markers of the antiphospholipid syndrome (APS), but may also directly contribute to the development of thrombosis and other manifestations, including the APS vasculopathy. The latter has been documented in leptmeninges, lung, skin, myocardium, peripheral arteries, and kidney. Renal lesions, a common feature of primary antiphospholipid...

article

Echocardiographic evaluation of patients with primary antiphospholipid syndrome

Nilda Espínola-Zavaleta, Jesús Vargas-Barrón, Terry Colmenares-Galvis, Flory Cruz-Cruz, more

American Heart Journal > 1999 > 137 > 5 > 973-978

Background A third to half of the patients with primary antiphospholipid syndrome have valve disease. Methods and Results The echocardiographic characteristics of primary antiphospholipid syndrome were analyzed, and the utility of treatment with anticoagulants and/or antiplatelet agents (acetylsalicylic acid) is examined with the use of transesophageal echocardiography in the evaluation of valvular...

article

6 Antiphospholipid syndrome in SLE

Mary-Carmen Amigo, Munther A. Khamashta, Graham R.V. Hughes

Bailliere's Clinical Rheumatology > 1998 > 12 > 3 > 477-493

The antiphospholipid syndrome, initially described in systemic lupus erythematosus (SLE), occurs in 20–35% of patients with this condition. Its clinical manifestations may precede, be concurrent with, or follow clinical featurs of SLE. There are no major differences between the primary antiphospholipid syndrome and the secondary form that associates with SLE. Several studies suggest that the presence...

article

The Antiphospholipid/Cofactor Syndromes: A Primary Variant with Antibodies to β ₂ -glycoprotein-I but No Antibodies Detectable in Standard Antiphospholipid Assays

Antonio R. Cabral, Mary Carmen Amigo, Javier Cabiedes, Donato Alarcon-Segovia

The American Journal of Medicine > 1996 > 101 > 5 > 472-481

background: Most systemic lupus erythematosus (SLE) patients with two or more clinical manifestations of the antiphospholipid syndrome (APS) and negative antiphospholipid antibodies (aPL) have antibodies to β ₂ -glycoprotein-I (aβ ₂ GP-I). Herein we describe a similar set of circumstances, but in patients without evidence of SLE.patients and methods: We studied 6 patients with recurrent...

article

Ocular Vaso-occlusive Disease in Primary Antiphospholipid Syndrome

Cristina Castañón, Mary-Carmen Amigo, José L. Bañales, Arnulfo Nava, more

Ophthalmology > 1995 > 102 > 2 > 256-262

Purpose: To evaluate the ocular involvement in patients with the primary antiphospholipid syndrome.Methods: The authors performed a cross-sectional ophthalmologic study of 17 patients with the primary antiphospholipid syndrome. Retinal fluorangiography was performed in 13 patients.Results: Visual symptoms were described by ten patients. Visual acuity was markedly decreased in five eyes. Conjunctival...

Filter options

Publication date

Last 3 years (2)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Mary-Carmen Amigo

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options